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Hepatocellular carcinoma (HCC) is one of the critical global health issues. As
indicated in cancer statistics, the disease is the third most common cause of cancer-
related deaths worldwide.
1 HCC is particularly prevalent in Asia, where hepatitis
B virus (HBV) is endemic.
2,3 Association of HCC with viral liver disease, which is
a unique entity, places this cancer in a complex one to be properly managed.
In general, the tumor stage and underlying liver function are both major
determinants of the treatment selection as well as prognosis in HCC patients.
4
Potentially curative therapies are offered to only limited patients, which are
estimated to be around 20%. Liver resection and liver transplantation are curative
treatments. However, surgical resection accompanies high recurrence rate, and
transplantation cannot be universally applicable. Radiofrequency ablation therapy
and percutaneous ethanol injection therapy are also used as curative treatments for
HCC.
5 Because HCC is frequently diagnosed at the intermediate or advanced
stages, transarterial chemoembolization (TACE), the most popular nonsurgical
alternative, is often used as a palliative treatment,
6,7 however, effective only in
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limited occasion. HCC is also resistant to current chemo-
therapeutic drugs.
During the past decade, there has been a major evolution
regarding the management of HCC; emergence of the cli-
nically proven drug for its efficacy and active use of radio-
therapy using either external photon or particle beam.
Sorafenib, a new targeting agent, is the first drug that
showed survival benefit in randomized clinical trial.
8,9
Despite of the significance shown in the trial, however, the
substantial gain in survival remains so modest that the
clinical usefulness is questioned in view of the cost-benefit
aspect. Its benefit needs to be further tested in various
therapeutic strategies.
Radiotherapy has not frequently been used for treatment
of HCC. This limitation results from the early reports that
radiation tolerance of liver was far less than the therapeutic
radiation dose,
10,11 hence, low level of therapeutic ratio.
However, recent technological developments have enabled
more successful treatment of HCC by delivering a subs-
tantial dose of radiation to the tumor and avoiding radio-
sensitive healthy normal organs in the vicinity. In Korea,
radiotherapy of HCC has been initiated in a single insti-
tute.
12-14 But now, the improved efficacy of radiotherapy
has been more widely understood and resulted in increas-
ing number of institutions adopting local radiotherapy for
advanced HCC,
15-18 as evidenced by soaring number of the
published reports (Fig. 1). 
However, it should be noted that HCC is a complex
disease with cancer and chronic liver disease. It also has a
great potential of intrahepatic and extrahepatic metas-
tasis.
19,20 Therefore, achieving the therapeutic success in
HCC seems quite possible through a multimodal team
approach, which is a basic condition for good perfor-
mance of radiotherapy for HCC. Besides, there are many
questions remaining unanswered. In this review, current
status of radiotherapy for HCC will be discussed with
regard to technical consideration and combination stra-
tegy. The limitation and future perspectives will also be
discussed. 
The basic strategy of radiotherapy is based on consi-
deration of tumor control and normal tissue toxicity, which
reflects radiosensitivity of the both elements. In radio-
therapy of HCC, radiosensitivity of tumor and normal
tissues haven’t been in favor of therapeutic success. Until
recently, radiosensitivity of HCC has been misunderstood
as resistant. This notion came from poor clinical outcome
of the early trials, which used insufficient radiation dose
for fear of radiation-induced liver toxicity.
21-23 Through the
accumulated experiences using substantial doses, radiosen-
sitivity of HCC has been revalued as sensitive.
17,18,24 Some
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Fig. 1.Number of publications on radiotherapy for liver cancer, shown through PubMed search. Radiotherapy of Hepatocellular Carcinoma
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exemplary patients’ cases are illustrated in Figs. 2 and 3. 
Not many investigations have been performed on radio-
biology of HCC. Recently, Tai, et al.
25 has developed a
radiobiologic model for primary liver tumors. Through
analyzing 3 published clinical series of primary liver
cancer treated with different dose fractionation, the radio-
biologic parameters were extracted; and tumor doubling
time (Td) were calculated as 15.0 ± 2.0 Gy, 0.01 ± 0.001,
and 128 ± 12 day, respectively. This model has several
weakness since it is based not on the individual clinical
data, but on the median values of treatment parameters.
Besides, it is based not on the tumor response, but on the
survival. The study population also involves primary liver
cancers other than HCC. However, a trial application
showed well fit to a selective clinical sample. Through
further modification, HCC-specific radiobiologic model is
expected to be developed in the near future.
For normal tissue effects on radiation, the critical volume
model has been proposed.
26,27 Based on the assumption that
normal tissue complication probability is determined by
the fraction of surviving functional subunits, an organ is
considered as the sum of multiple functional subunits
which are arranged either serially or in parallel. Since liver
belongs to parallel organ group, damage to a portion of
liver may not impair the entire liver function. Because the
remaining portion can maintain the organ function inde-
pendently, overt complication occurs only when a critical
volume of the organ is damaged. This is a key concept in
radiotherapy of HCC; as long as the volume irradiated is
limited, radiation dose can be escalated to the tumoricidal
level without deteriorating liver function. Furthermore,
liver is a unique organ that has a proficient regenerative
potential. In fact, radiation dose could be escalated to
higher than 70 Gy in a limited volume of the liver.
28
In clinical application, situation looks more complex
with several intercepting factors; presence of concurrent
chronic liver disease in majority of patients and frequent
use of combination treatment. Concurrent chronic liver
diseases, which are more frequent in Asian patients, might
deteriorate hepatic functional reserve. Combination treat-
ment might also alter the hepatic functional reserve. In an
animal experiment using rats with liver cirrhosis, concur-
rent treatment of partial liver radiation and 5-Fu chemo-
therapy significantly increased lethality.
29 Therefore,
radiation dose prescription needs to be tailored according
to clinical situation, assuming that the hepatic tolerance to
radiation would be modified. 
Since the liver is in close proximity with many abdominal
organs, toxicity of surrounding gastrointestinal organs
should be taken into consideration. Normal tissue tolerance
doses that have been defined as TD5/5 (tolerance dose
representing the 5% complication rate 5 years after irra-
diation) and TD50/5 (tolerance dose representing the 50%
complication rate 5 years after irradiation) remain as
Fig. 2. Illustration of an exemplary patient treated with TACE plus radiotherapy (54 Gy) for locally advanced HCC. CT scan images are shown for preTACE (A), postTACE
(B), postradiotherapy (C), and postresection (D). Note tumor regression as well as compensating hypertrophy of uninvolved liver. No tumor cells were found in surgical
specimen. HCC, Hepatocellular carcinoma; TACE, transarterial chemoembolization.
ABCD
Fig. 3. Illustration of an exemplary patient treated with concurrent radiotherapy (45 Gy) and intraarterial chemotherapy for locally advanced HCC accompanied with
portal vein tumor thrombosis. CT scan images of pretreatment (A) and posttreatment (B) are shown. Tumor regression in the primary and portal vein is noted, followed
by curative surgical resection (C). HCC, Hepatocellular carcinoma.
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valuable guides.
30,31 However, presence of other predisposing
factors needs to be in consideration, including other medi-
cal illness, past history of cancer treatment as well as
content of the present treatment such as concurrent che-
motherapy. In general, stomach and small bowel should be
limited to 45 Gy and colon to 50 to 54 Gy. Since these
organs belong to serial type, attention should be paid not to
generate focal overdose area beyond the tolerance level. 
Technological advances in radiotherapy involve develop-
ment in imaging technology as well as computer tech-
nology, and these advances have influenced the whole
process of radiotherapy, ranging from treatment planning,
and dose delivery to response assessment.
For planning, the bottom line will be CT-based confor-
mal planning. Through this process, beam optimization
can be possible for conformal coverage of the tumor as
well as avoiding critical normal tissues. Computer calcula-
tion of dose-volume statistics provides information that
can be used for dose prescription. Depending on the
volume of normal liver to be saved, the dose to the gross
tumor volume can be determined. Several published gui-
deline suggests to deliver differential radiation doses by
volume of normal liver to be irradiated (Table 1). Briefly,
3 types are popularly used in the published reports; volume
parameter (V50%, 50% of the isocenter dose).
14,32,33 normal
tissue complication probability (NTCP) at 5% risk of
radiation induced liver disease,
34-36 and mean dose to nor-
mal liver.
34,37 Consensus hasn’t been reached yet regarding
to which level radiation dose can be safely delivered.
Therefore, this is an another area of future study.
Since the radiotherapy planning is a precise perfor-
mance, beam delivery should also be closely monitored for
presence of uncertainty in actual beam delivery. Consider-
ing that liver is a moving organ and moving distance also
varies according to the anatomical position in liver segment,
monitoring of uncertainties is particularly important in
treating HCC. Generally, 2 types of uncertainties are
identified; intra- and inter-fractional.
38 The variability in
liver position has been observed in non-breathhold stereo-
tactic body radiotherapy, showing interfraction variability
as an important source of geometric uncertainty with rather
minimal extent in intrafraction change in liver motion.
39  To
mitigate unwanted problems arising from uncertainties,
image guided radiotherapy (IGRT) technique is essential. 
Clinically, several options of IGRT are in use.
39-41 The
simplest way is to cephalocaudally extend the physical
target volume margin. This method needs fluoroscopic
assessment of the organ motion for its excursion distance.
Abdominal pressure or breath hold technique with active
breath control can also be possible. Since the magnitude of
breath control varies, these techniques basically require
image guided monitoring. Another technique involves
treatment of the entire moving path of the liver during free
breathing using 4-dimensional CT scan imaging. In this
technique, the timing of CT images and the position of
external fiducial markers are synchronized. More advanced
techniques involve gated radiotherapy and tumor tracking.
In gated radiotherapy, external surrogates are used for
reference point in monitoring tumor position. Finally, the
most accurate method seems to be real-time tracking of
tumor motion.
42 In this technique, radio-opaque fiducial
markers are implanted in or near the tumor. These markers
are used to create a coordination system for image guidance
involving real-time tracking of tumor motion. Through
dynamic track-and treat options, gating of the treatment
beam can be performed. 
Although sophisticated technologies are developed,
problems still exist; high cost in hardware and labor-
intensive process involving treatment planning, beam
delivery, and quality control. For better distribution and
easier application in daily practice, the technology needs to
be further simplified and cost-friendly. 
TECHNICAL CONSIDERATION
Table 1.Recommended Radiation Dose-Volume to Normal Liver in Radiotherapy of HCC
Parameter Category Recommended dose References
V50% (50% of the   isocenter dose) < 25% 59.4 or higher 14, 32, 33
25 - 49% 45 - 54
50 - 75% 30.6 - 45
> 75% No treatment
NTCP model (5% risk of RILD) 1/3 liver 43 - 93 Gy 34 - 36
*1.5 Gy daily 2/3 liver 34 - 47 Gy
Whole liver 30 - 35 Gy
Mean dose to normal liver Conventional fraction < 28 - 32 Gy 34, 37
Hypofraction in 6     < 18 Gy
HCC, Hepatocellular carcinoma; NTCP, normal tissue complication probability; RILD, radiation-induced liver disease.Internal radiotherapy
Radiotherapy is classified to internal and external radio-
therapy. Internal radiotherapy is performed by delivering
radioisotopes through either percutaneous or transarterial
approach. The ideal conditions for the radioisotopes involve;
a short half life and beta ray emitting as a therapeutic
purpose but with a little portion of gamma ray for verifica-
tion. Three types of isotopes have been reported; Yttrium-
90 (
90Y), a pure beta emitter with a physical half life of 2.7
days, has been attempted by intratumoural injection of 
90Y
glass microspheres
43,44 under ultrasonographic guidance or
by transarterial approach. Iodine-131 (
131I), mostly beta and
a little gamma emission with a half-life of 8 days, has been
applied in a form of 
131I-lipiodol.
45,46 Homium-199 (
199Ho),
mostly beta and a little gamma emission with a half-life of
26.8 h, has also been tried in chitosan complex form either
intratumorally or transarterial approach.
47,48 Substantial
success has been achieved through these treatment, how-
ever, there remain several problems. Unwanted leak of the
isotopes may happen through the vascular shunts, which
frequently accompany HCC. Dose distribution in and
around the tumor also remains to be defined.
49 The indica-
tion for internal radiotherapy appears to be limited to rather
smaller tumors than the advanced ones. Although more
discussion will be required regarding internal radiotherapy,
this review will focus on external radiotherapy. 
External radiotherapy 
External radiotherapy can be applied alone or, more
popularly, in combination with chemotherapy. Early trials
of external radiotherapy for HCC adopted whole liver
radiation of no more than 21 Gy with chemotherapy.
21-23
These trials failed to show a therapeutic success, however,
it gave a lesson that combination of chemotherapy and
radiation may have potential benefit. Current consensus is
to treat not the whole but the focal liver with therapeutic
dose of radiation. 
For small tumors, radiotherapy alone can successfully be
performed with high tumoricidal level of radiation dose. In
this case, radiation fractionation can be either in conven-
tional or in hypofractionation. A French group performed a
prospective phase II trial of conformal radiotherapy.
32
Radiotherapy of 66 Gy in conventional fractionation has
been done for 27 HCC patients with small tumors which
were either single nodule smaller than 5 cm or 2 nodules,
each larger than 3 cm. The result was excellent with a
response rate of 92%. However, they also experienced
substantial toxicity; 19% grade 3 in Child-Pugh score A
group and 22% grade 4 in score B group. In other retro-
spective reports, radiotherapy with higher doses was shown
to achieve similar success.
16
Small tumors appear to be the best candidates for stereo-
tactic body radiation therapy (SBRT) using hypofractio-
nation. Since the first trial in 1995, SBRT has been per-
formed in various dose fractionation schemes on liver
tumors both primary and metastatic.
50-52 Canadian group
reported a phase I trial for 31 HCC patients. With the
median dose 36 Gy (between 24 and 54 Gy) in 6 fractions,
they achieved 65% local control rate in 12 months and
overall median survival time of 11.7 months.
53
Combination therapy of external radiotherapy and 
chemotherapy
Radiotherapy alone can be an effective modality for small
tumours. However, in treating locally advanced tumours,
radiation doses are limited by liver tolerance, particularly
for patients with cirrhosis. In Asia, where TACE has been
a major nonsurgical option, radiotherapy has been intro-
duced to improve the high rates of progression after TACE.
TACE, using iodized poppy seed oil, Lipiodol and the
anticancer drug, has been a popular treatment in Asia.
However, its limitation has also been well documented as
demonstrated in the pathologic evidence from patients who
later underwent resection.
54,55 Tumors remain viable parti-
cularly in and around the capsule and may recur via the
blood supply from collateral circulation or recanalization
of the originally embolized artery. Even in encapsulated
tumors, which are the favorable tumor type for TACE, the
necrosis rate is reported to be no more than 44% when
HCCs are larger than 3 cm.
56 In locally advanced HCCs, it
is almost impossible to achieve a measurable response. 
Radiotherapy can effectively ameliorate the limitations
of TACE through its antitumor activity as well as anti-
vascular activity.
57 Radiation may also interact with the
chemotherapeutic drug while the drug stays in the tumors
after TACE. Adriamycin, injected at the time of TACE, is
well known to augment the antitumor efficacy of radia-
tion.
58 This drug, when mixed with Lipiodol, has been
reported to maintain relatively high concentration in tumors
as long as 27 days and decrease to a trace level after 47
days.
59,60 In the first report of combination treatment of
TACE and radiation by Seong, et al.,
12 tumor response rate
was 63.3%. Survival rates at 1, 2, and 3 years were 67%,
33.3%, and 22.2%, respectively, with the median survival
time of 17 months. Considering the patients’ characteris-
tics, all with stages III or IVa with large tumors (mean
tumor diameter 8.95 ± 3.4 cm), this regimen seemed to be
effective. Radiotherapy has also been attempted to salvage
HCC patients who failed with TACE, giving 66.7% res-
ponse rate and median survival time of 14 months.
13
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PRACTICE OF RADIOTHERAPY FOR
HEPATOCELLULAR CARCINOMAIn the retrospective comparative study by the same group,
a statistically significant improvement in survival was seen
in patients treated with TACE+RT compared to TACE
alone (2-year survival rate 37% versus 14% for RT versus
repeated TACE, p = 0.001) (Fig. 4).
61 The survival dif-
ference was greatest for larger tumours. The 2 year survival
rates for TACE + radiotherapy and TACE alone were 63%
versus 42% in 5-7 cm tumors, 50% versus 0% in 8-10 cm
tumors, and 17% versus 0% in tumors larger than 10 cm,
respectively.
61 Similar results have been shown in other
reports.
62-65 Recently, Chinese group underwent a meta-
analysis questioning the benefit of TACE plus radiotherapy
by comparing to TACE alone for unresectable HCC.
Through analyzing a total of 1,476 patients from 5 ran-
domized controlled trials and for 17 nonrandomized trials,
they concluded that both tumor response and survival
outcome were benefited with radiotherapy.
66 
Combination of chemotherapy and radiotherapy trial has
been actively performed by Michigan group.
18,67 They
performed conformal hyperfractionated radiotherapy (1.5
Gy twice daily over 6 to 8 weeks) with concurrent hepatic
arterial floxuridine in serial phase I/II studies of unresec-
table HCC. In the latest phase II study, the median survival
of 15.2 months has been reported in 25 HCC patients
treated with doses as high as 90 Gy,
28 providing a rationale
for high dose local radiotherapy for HCC. They have pro-
posed a practical guideline, suggesting that higher radiation
dose can be delivered if the radiation volume is limited to
the partial liver. Another approach of concurrent chemora-
diotherapy has been performed in stage IVa HCC patients.
68
Han, et al.
69 reported promising survival results of conformal
RT combined with hepatic arterial chemotherapy of 5-FU
and cisplatin in 40 patients with locally advanced HCC
with portal vein tumour thrombosis (PVTT).
69 
Table 2 summarizes selective series of radiotherapy in
combination with chemotherapy either in TACE or in
regional chemotherapy. Some series show promising sur-
vival outcome. However, the benefit is obscured due to the
nature of mostly retrospective or phase I, II trials and hetero-
geneity in radiation doses as well as the patient charac-
teristics. Prospective trials are required to confirm the
efficacy of chemoradiotherapy. 
Association of PVTT in locally advanced HCC has been
known to severely limit the therapeutic option, including
TACE and poor survival outcome as well.
70 In their study,
the 3 year overall survival rate was 24.1% and the median
survival time was 13.1 months, which was superior the
previously reported survivals of 4-6 months. The treatment
outcomes have been updated for 101 patients, showing a
median survival of 16.7 months (Fig. 5).
71 Combination
strategies have also been attempted with antiangiogenics
by a Japanese group.
72 Hyperfractionation RT of 45-75 Gy
(1.5 Gy fractions bid) was combined with thalidomide in
121 HCC patients, showing 60% survivals at 1 year and
45% at 2 year. 
Different approaches have been attempted for HCC
patients with PVTT. Since PVTT is a major obstacle to
perform TACE, some groups used radiotherapy for the
Jinsil Seong
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Table 2.Selective Series Reporting Clinical Results of Chemoradiotherapy for Locally Advanced HCC
Series
Patient 
Treatment
RT dose Overall  survival    Median survival 
number (Gy) rate (%) (months)
Yasuda, et al.
62 44 TACE + RT 36 - 70 81 (3y) NA
Guo, et al.
63 76 TACE + RT 30 - 50 64 (1 y); 19 (5 y) 19
Seong, et al.
15 158 TACE + RT 25.2 - 50 59 (1 y); 9 (5 y) 16
Zeng, et al.
65 54 TACE + RT 36 - 60 72 (1 y); 24 (3 y) 20
Park, et al.
16 59 RT (48 failed TACE) 30 - 55 47 (1 y); 27 (2 y) 10
Ben-Josef, et al.
28 35 ia FudR + RT 40 - 90 57 (1 y); 11 (3 y) 15.2
Han, et al.
69 40 ia 5-FU + RT (with PVT) 45 57.6 (1 y); 24.1(3 y) 13.1
HCC, Hepatocellular carcinoma; TACE, transarterial chemoembolization. Tx, treatment; RT, radiotherapy; CR, complete response; PR, partial 
response.
Fig. 4. Survival outcome after treatment with either TACE alone (broken line) or
TACE plus radiotherapy (solid line) for similar clinical group of HCC patients. The
2 year survival rate appears higher in TACE plus radiotherapy group (36% vs.
14%, p < 0.05, Log-rank test). TACE, transarterial chemoembolization; TACE + RT,
transarterial chemoembolization radiotherapy; HCC, Hepatocellular carcinoma.purpose of opening of PV.
73,74 By including only PVTT
within a radiation volume, the response rate of PVTT was
between 20% and 100%, and complete response was
shown around 30%. Other group included PVTT as well
as primary tumor within a radiation volume.
69,75-78 The res-
ponse rate as a whole was between 39 to 71.4% with com-
plete response less than 10%. Survival outcome seemed
higher in the latter approach. It seems that targeting PVTT
only can be useful to open PV in some occasions however,
overall outcome seems better with treating both the pri-
mary tumor and PVTT. The selected results are sum-
marized in Table 3.
Particle beam radiotherapy 
The unique characteristic of charged particle beam, the
Bragg peak, allows deposition of high dose of radiation
within the target and then sharp dose fall off beyond the
target. In addition, charged particle beams do not disperse,
which result in sharp lateral margins.
79 These characteristics
as well as greater radiobiological effectiveness shown in
carbon ion beam appear to be fascinating to treat HCC.
Tsukuba group in Japan reported the largest series of 162
HCC patients treated with median 72 Gy with or without
TAE.
80 The results were; the 5 year local control 87% and
5 year survival rate 23.5%. They also showed that repeated
proton treatment was safe in selected group of patients. A
few more phase II trials have been reported showing that
proton beam treatment is safe and effective. However, the
advantage of the Bragg peak is somewhat compromised in
the process of beam spreading modulation to encompass
Radiotherapy of Hepatocellular Carcinoma
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Table 3. Selective Series Reporting Clinical Results of Radiotherapy for Locally Advanced HCC with Portal 
VeinTumor Thrombosis
Author Tx volume N  Treatment 
RT dose   Response Median survival
(Gy) rate time  (months) 
Zeng, et al.
73 PVT  44  RT + TACE 
50  CR 34.1%, RT: 8,
(36 - 60)  PR 11.4%  non-RT: 4 
Nakagawa, et al.
74 PVT 52  RT 
57 
50%  3 year: 15.2%
(39 - 60) 
You, et al.
75 PVT
49  RT + TACE  40 - 45  48% 
TACE: 13
+ primary  TACE+RT: 13.5 
Kim, et al.
76  PVT
41  RT  44 - 54  
CR 9.7%,  Responder: 20.1
+ primary  PR 29.3%  Nonresponder: 7.2 
Kim, et al.
77 PVT
59  RT  30 - 54  
CR 6.8%, Responder: 10.7
+ primary  PR 39%  Nonresponder: 5.3 
Kim, et al.
78 PVT
54  RT + ia 5 FU  45  42.1%  11.6
+ primary 
Kim, et al.
71 PVT
101  RT + ia 5 FU  45  43%  16.7
+ primary 
HCC, Hepatocellular carcinoma; TACE, transarterial chemoembolization. Tx, treatment; RT, radiotherapy; CR, complete response; PR, partial 
response.
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Fig. 5. Survival outcome after concurrent radiotherapy and intraarterial
chemotherapy for HCC patients with portal vein tumor thrombosis. Note median
survival time of 16.7 months and 2 yr survival rate of 33.7%. HCC, Hepatocellular
carcinoma.
A
Blarge tumor volume. Toxicity seems greater than expected
with gastrointestinal complication (9%) and hepatic
dysfunction (13%). 
Carbon ion beam treatment has first been reported by
Kato, et al.
81 In phase I-II trial of 49.5-79.5 cobalt gray
equivalents in 15 fractions for 24 patients, 5 year local
control was 81% and 5 year survival was 25%. Particle
beam treatment is expected to improve the treatment out-
come in the future. However, high cost in purchase,
installation and maintenance of hardware is an another
problem. Also, technology needs further development to
perform perfect intensity modulated particle beam therapy.   
Although much progress has been done, there remain many
issues unsolved. In this section, some of these are discussed,
including optimum dose-fractionation schedule, intra- or
extrahepatic metastasis after radiotherapy, and radiation-
induced hepatic dysfunction.
Optimum dose-fractionation
In several studies, a radiation dose was shown as a signifi-
cant prognostic factor in HCC. Dose escalation resulted in
increased response rate.
24 The radiation dose was also
found to be a significant prognostic factor for survival.
15,82
Since delivery of tumoricidal dose seems possible if the
effective liver volume irradiated is limited to a certain level
(i.e., 25%), substantial tumor response can be achievable in
selected patients. Importantly, the information of dose-
volume statistics through 3-D planning is required as a
basic requirement. 
Literature survey shows that a variety of fractionation
has been adopted; hyperfractionation in b.i.d. schedule,
conventional fractionation, and hypofractionation. In ret-
rospective cohort study of Seong, et al.,
82 various dose frac-
tionations have been used, ranging from conventional to
extreme hypofractionation, using stereotactic technology.
Better prognosis was shown in higher doses that have been
calculated and analyzed in biological effective dose (Fig. 6). 
Escalation of radiation dose brings not only improved
tumor response, but also increased toxicity. For example,
liver toxicity increased to the double level (from 4.2% to
8.4%) when the radiation dose was escalated from < 40 Gy
to > 50 Gy. Gastrointestinal toxicity increased almost to the
triple level (from 4.2% to 13.2%) in the same situation.
15
Close proximity of radiosensitive gastrointestinal organs is
considered as contraindication to this approach. 
In determining radiation dose that can safely be deli-
vered, several dose-volume(DVH) guidelines are de-
veloped, as shown in Table 1. Briefly, radiation doses are
determined by the volume of liver that is irradiated. DVH
guideline has also been introduced with additional
parameter representing liver reserve function. Cheng et
al.
83  presented a dose prescription guideline, based on
volume and indocyanine green retention test.
Taken together, the best tumor control is expected with
higher radiation dose, however, with possible toxicity to
liver as well as adjacent gastrointestinal organs. Therefore,
consensus is required regarding detailed guideline involv-
ing DVH data and other factors that might influence toxicity. 
Intra- or extrahepatic metastasis after radiotherapy
The nature of hepatocellular carcinoma involves presence
of vascular invasion in its early stage.
19,20 It is also a major
contributing mechanism to intrahepatic relapse as well as
extrahepatic metastasis to remote organs. It explains why
intra- or extrahepatic relapse soon follows after substantial
tumor regression by local treatment involving external
beam radiotherapy of radiofrequency ablation. Therefore,
it seems quite rational to perform combination strategy of
local modality and systemic modality.
84 Radiotherapy can
be combined with transarterial chemoembolization to
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remedy its weakness, with chemotherapy or with new
targeting agents. This approach has been proven to achieve
substantial tumor regression even in the advanced disease
with accompanying portal vein tumor invasion. A number
of novel molecular targeting agents have now been devel-
oped and waiting for the results of clinical tests.
8,9 Combina-
tion of local radiotherapy and novel molecular targeting
agents is expected to bring improved results. 
Cancer metastasis occurs after incomplete treatment.
Even TACE has been reported to enhance metastasis unless
complete treatment has been done. For post radiotherapy
metastasis, suspicion has been raised for possible enhanced
metastasis by radiation. Several reports have suggested
molecular mechanisms that radiation might enhance metas-
tasis.
85,86 Cheng, et al.
85 showed that radiation up-regulates
prometastatic molecule, matrix metalloproteinase (MMP)-
9. This area of endeavour needs further investigation and
ultimate identification of the key molecules will be helpful
in improving treatment outcome. 
Redefinition of radiation-induced liver toxicity
Traditionally, radiation-induced toxicity in liver has been
defined as radiation-induced liver disease (RILD), a clinical
syndrome of anicteric hepatomegaly, ascits, and elevated
liver enzymes (serum alkaline phosphatase) occurring
typically 2 weeks to 4 months after radiotherapy. While this
concept fits in case of radiotherapy alone, different types of
toxicity are frequently seen in combined modality strategy
with chemotherapy.
36 This entity has been named for
combined modality liver disease (CMILD); it presents
jaundice and right upper quadrant pain more frequently as
well as elevation in bilirubin and serum aspartate trans-
ferase.
11 CMILD is more lethal with 30-50% mortality.
With development of novel targeting agents, combined
modality-induced liver toxicity feature might differ from
the classic concept. Adoption of general concept “hepatic
dysfunction” needs to be seriously considered.
Technical advance as well as deeper understanding of
radiobiology increase the use of radiotherapy in manage-
ment of HCC. Radiotherapy has been proven not only for
the palliative benefits for symptomatic patients but also for
potentially curative treatment for selected patients by
delivering therapeutic dose of radiation in a variety of
strategies. Continued progress is being made in technical
development as well as newly developed molecular
targeting agents, which will bring more opportunity for
improved outcome. However, major hepatology societies
do not still include this modality in the practice circle for
HCC. The most urgent thing to convince these societies is
to perform prospective randomized trials to test the
efficacy of radiotherapy in HCC. Refinement of radio-
therapeutic technology and development of new com-
bination strategy should also be performed in parallel. 
.
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